Follicular lymphoma
MONDO:0018906Follicular lymphoma is a form of non-Hodgkin lymphoma characterized by a proliferation of B cells whose nodular structure of follicular architecture is preserved.
Also known as: follicle center lymphoma, follicle centre lymphoma, follicular center cell lymphoma, follicular centre cell lymphoma, follicular non-Hodgkin lymphoma, follicular non-Hodgkin's lymphoma, lymphoma, follicular center cell, lymphoma, follicular centre cell
2516 clinical trials for this condition and its sub-types, 590 tagged with Follicular lymphoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Double-Drug attack on Hard-to-Treat lymphomas
Disease control Stopped earlyResearchers are testing whether combining two chemotherapy drugs, pralatrexate and romidepsin, is safe and effective for people with lymphoid cancers that have returned or stopped responding to treatment. The trial first finds the highest dose people can tolerate, then gives that…
Phase 1/2 • Sponsor: Jennifer Amengual • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New hope for tough blood cancers: experimental drug enters human testing
Disease control Stopped earlyThis early-stage study is testing an experimental drug called BGB-21447 in about 112 people with certain blood cancers (like lymphoma or leukemia) that have returned or not improved after prior treatments. The main goal is to find a safe dose and check for side effects, while als…
Phase 1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New cell therapy shows promise for tough-to-treat lymphoma
Disease control Stopped earlyThis study tests an experimental treatment called GLPG5101 for people with B-cell non-Hodgkin lymphoma that has come back or not responded to standard therapy. The treatment is a cell therapy made at the hospital. The study has two phases: first, finding the best dose with the fe…
Phase 1/2 • Sponsor: Lakefront Biotherapeutics NV • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New pill for ulcerative colitis shows promise, but trial halted early
Disease control Stopped earlyThis study tested an oral medication, NX-13, in 81 adults with moderate to severe ulcerative colitis. Participants received either NX-13 or a placebo for 12 weeks, with a long-term follow-up option. The trial was terminated early, so the full results are not available, but the da…
Phase 2 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New targeted therapy shows promise for Tough-to-Treat lymphomas
Disease control Stopped earlyThis study tests a drug called loncastuximab tesirine in adults with B-cell lymphomas that have returned or not responded to prior treatment. The drug works like a smart bomb, attaching to a marker on cancer cells and delivering chemotherapy directly to them. The main goal is to …
Phase 2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Cord blood transplant trial for blood cancers halted early
Disease control Stopped earlyThis study looked at using umbilical cord blood transplants after strong chemotherapy and radiation to treat various blood cancers like leukemia and lymphoma. It involved 200 participants and aimed to see how many were alive one year after transplant. The trial was stopped early,…
Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New pill aims to tame ulcerative colitis Flare-Ups
Disease control Stopped earlyThis study tested an experimental daily tablet called VTX002 in people with moderate to severe ulcerative colitis, a chronic inflammatory bowel disease. About 213 participants were randomly assigned to receive one of two doses of VTX002 or a placebo for 13 weeks, with the option …
Phase 2 • Sponsor: Oppilan Pharma Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Experimental lymphoma drug IPH6501 tested in early trial – but study halted
Disease control Stopped earlyThis early-phase trial tested an experimental drug called IPH6501 in 23 people with certain types of Non-Hodgkin lymphoma that had returned or stopped responding to prior treatments. The goal was to check safety and find the right dose, while also looking for signs that the drug …
Phase 1/2 • Sponsor: Innate Pharma • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Experimental lymphoma drug CPO107 tested in small early trial
Disease control Stopped earlyThis early study tested a new drug called CPO107 in 7 people with advanced CD20-positive Non-Hodgkin lymphoma who had no other good treatment options. The goal was to find a safe dose and see how the body handles the drug. The trial was stopped early, so we have limited informati…
Phase 1 • Sponsor: Conjupro Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Experimental combo for tough lymphoma shows early promise, but trial halted
Disease control Stopped earlyThis early-stage trial tested a combination of two oral drugs, tazemetostat and venetoclax, in people with non-Hodgkin lymphoma that had come back or stopped responding to treatment. Only 3 people enrolled before the study was terminated. The main goals were to find the safest do…
Phase 1 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New lymphoma drug trial halted early after testing in 18 patients
Disease control Stopped earlyThis early-stage trial tested a drug called VAY736, alone or with other cancer drugs, in 18 adults with certain types of Non-Hodgkin Lymphoma that had come back or not responded to prior treatments. The main goals were to check safety and find the right dose. The study was termin…
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Experimental drug voruciclib tested in desperate blood cancer patients
Disease control Stopped earlyThis early-phase trial tested an experimental drug called voruciclib, either alone or combined with another drug (venetoclax), in adults with several types of blood cancers (like lymphoma, leukemia) that had come back or stopped responding to prior treatments. The main goal was t…
Phase 1 • Sponsor: MEI Pharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Experimental donor CAR-T therapy tested in lymphoma – trial halted early
Disease control Stopped earlyThis early-phase trial tested a new therapy called ATA3219, which uses immune cells from a healthy donor to attack cancer cells in people with relapsed or refractory B-cell non-Hodgkin lymphoma. The study aimed to check safety and see if the treatment works, but it was stopped ea…
Phase 1 • Sponsor: Atara Biotherapeutics • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New cancer drug PRO1160 tested in advanced cancers – trial ends early
Disease control Stopped earlyThis study tested a drug called PRO1160 in people with advanced kidney cancer, nasopharyngeal cancer, or non-Hodgkin lymphoma. The goal was to find a safe dose and see if the drug shrinks tumors. The trial was stopped early, so results are limited.
Phase 1/2 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Promising combo for lymphoma hits early snag – trial stopped
Disease control Stopped earlyThis phase 2 study tested umbralisib (a PI3K blocker) plus rituximab (an antibody that targets B-cells) as the first treatment for people with follicular or marginal zone lymphoma. The goal was to see how many patients had their tumors disappear completely. Only 18 people enrolle…
Phase 2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Experimental cell therapy for tough blood cancers put on hold
Disease control Stopped earlyThis early-stage study tested a new treatment called CNTY-101 for people with B-cell cancers that came back or didn't respond to other therapies. The main goals were to find a safe dose and see if the treatment could shrink tumors. The study was stopped early, so results are limi…
Phase 1 • Sponsor: Century Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Drug combo aims to control Slow-Growing lymphoma without chemo
Disease control Stopped earlyThis phase 2 study tested a combination of two drugs, lenalidomide and rituximab, in 30 people with previously untreated indolent non-Hodgkin's lymphoma. The goal was to see how well the drugs worked together to shrink or control the cancer. Participants took lenalidomide daily f…
Phase 2 • Sponsor: University of California, Davis • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Early scope procedure fails to show clear benefit in severe pancreatitis trial
Disease control Stopped earlyThis study tested whether doing an early endoscopic ultrasound and removing any gallstones from the bile duct could help people with severe pancreatitis caused by gallstones. The trial planned to enroll many patients but was stopped early after only 27 participants. The main goal…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Keytruda trial for untreated lymphoma halted early
Disease control Stopped earlyThis phase II study tested the immunotherapy drug pembrolizumab (Keytruda) in 9 people with untreated follicular lymphoma or marginal zone lymphoma. The goal was to see if the drug could shrink tumors or slow the disease. However, the trial was terminated early, so we have very l…
Phase 2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New transplant method shows promise for tough blood cancers
Disease control Stopped earlyThis study tested a bone marrow transplant using a partially matched family donor for people with blood cancers like leukemia. The goal was to see if a milder conditioning regimen and a drug called cyclophosphamide could help patients survive at least 180 days after transplant. T…
Phase 2 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New dual-targeting CAR t therapy tested for hard-to-treat lymphoma
Disease control Stopped earlyThis early-phase study tested a new treatment called bbT369 for people with a type of blood cancer (B cell non-Hodgkin's lymphoma) that had come back or stopped responding to other treatments. The therapy uses a patient's own immune cells, which are modified to better recognize a…
Phase 1 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Can a headband spot Alzheimer's? new study tests brain wave device
Diagnosis Stopped earlyThis study tested whether a wearable EEG device can help doctors diagnose Alzheimer's disease and mild cognitive impairment. Researchers compared brain wave data from the EEG with standard memory and thinking tests in 148 participants. The goal was to see if the EEG could improve…
Sponsor: Boston University • Aim: Diagnosis
Last updated Jun 27, 2026 08:04 UTC
-
New tool aims to help seniors with dementia make safer choices about guns
Knowledge-focused Stopped earlyThis pilot study tested a decision aid designed to help older adults with early dementia or depression think about safer ways to store firearms at home. Only 5 people took part, and the study was ended early. The goal was to see if the tool was practical and acceptable, and wheth…
Sponsor: University of Washington • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC